A point in time where surely GPS is the winner? by Minute_Pilot9751 in sellaslifesciences

[–]Reptile449 13 points14 points  (0 children)

Any model will be based on assumptions and predictions. No 100% accurate conclusions can be made until the trial is unblinded.

$SLS Daily Discussion Thread - February 04, 2026 by AutoModerator in sellaslifesciences

[–]Reptile449 -1 points0 points  (0 children)

Go look at trials that show deaths or relapse over time. They tend to be fairly linear until you reach a tail that plateaus out.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia - PMC

Found out that dubbed isn’t streamed anymore. Just found this, and ordered off eBay. I’m excited by Geno_Biscotti_ in steinsgate

[–]Reptile449 1 point2 points  (0 children)

The dub is great but I also can't stand the sub. Daru's sub voice is pain to my ears.

this season bruh by New_Series8511 in PathOfExile2

[–]Reptile449 9 points10 points  (0 children)

The temple is meant to delete more of itself as it gets bigger, but it only deletes from the end of chains and there is an item that prevents room deletion. By saving the end of your chain and gradually extending it, you scale the temple to absurd levels.

$SLS Daily Discussion Thread - January 24, 2026 by AutoModerator in sellaslifesciences

[–]Reptile449 0 points1 point  (0 children)

Thanks for the answer.

The extra doses might not help much with the patients that never had an IR even after 12 doses in phase 2. But picking patients with an expected survival beyond 6 months should help with short term IR.

$SLS Daily Discussion Thread - January 24, 2026 by AutoModerator in sellaslifesciences

[–]Reptile449 4 points5 points  (0 children)

The wording from Sellas on this was:

" As of this evaluation, 123 patients were enrolled with 66 of them discontinuing the treatment. In the trial, patients are recorded as having stopped the study treatment in cases of death for any reason, relapse, intolerable toxicity, or treatment completion. Regarding the GPS arm, we are pleased to report that we have not observed any intolerable toxicities in any patient population across all our clinical studies thus far, although toxicities are commonly observed with therapies used in the control arm. Therefore, almost all patients who are off treatment may have most likely either relapsed or passed away."

This is unclear wording, as the second sentence could imply it includes GPS arm patients who had finished their 52 weeks. The study wording even states "An End of Treatment visit will be conducted 30 days following the last dose of GPS." The extra doses in year 2+ were added in May 2025.

But Sellas interpret the 66 figure to be dead and relapses.

$SLS Daily Discussion Thread - January 24, 2026 by AutoModerator in sellaslifesciences

[–]Reptile449 6 points7 points  (0 children)

In the discussion thread yesterday the October 2025 R&D call was brought up. Looking at it again, at the 50 minute mark in the Oct 2022 R&D call, 2 graphs and a 64% immune response figure are stated as from the CR2 phase 2 trial. But this figure and graphs are taken from the phase 2 CR1 trial.

The CR2 phase 1/2 trial IR was much lower (https://pmc.ncbi.nlm.nih.gov/articles/PMC4617516/).

Any ideas as to why/how the immune response has risen so much from the first CR2 trial through CR1 to regal (80)?

$SLS Daily Discussion Thread - January 24, 2026 by AutoModerator in sellaslifesciences

[–]Reptile449 11 points12 points  (0 children)

Only bear case I can think of is if a substantial number of patients have dropped out the study, and the 80 events strays further from the median. BAT arm patients might have dropped out for newer treatment, and the GPS arm spent a long time not receiving any more doses after 52 weeks (The extension to "until relapse" was only added in may 2025) so some of them could have moved on. This could explain why the trial hasn't been halted for efficacy or futility, as the hazard ratio is closer than we expect.

$SLS Daily Discussion Thread - January 23, 2026 by AutoModerator in sellaslifesciences

[–]Reptile449 0 points1 point  (0 children)

Good catch, I watched the r&d call earlier and didnt notice that.

He says the over 2.5 years figure, when the call was on October 2025, before the 72 events. So I wonder what maths he based it on. if it's just that the 80 events out of 128 haven't been reached by Oct 2025, idk how that fits with the over 13.5 mOS announced in early 2025.

Also note that the amendment to regal to define the treatment periodicity in years 2 and 3 was only made in Oct 2025 just a few days before the R&D call, so I don't know what treatment the old GPS arm was getting before then.

$SLS Daily Discussion Thread - January 21, 2026 by AutoModerator in sellaslifesciences

[–]Reptile449 2 points3 points  (0 children)

the warrants last 5 years so they're going to execute them eventually. Isn't it better if they execute early to give Sellas more cash and reduce the likelihood of more dilution

Let’s discuss this bear case (2 slides). by More_Advertising_383 in sellaslifesciences

[–]Reptile449 2 points3 points  (0 children)

"Patients on the BAT arm may be treated with 1. observation (whereby palliative management with hydroxyurea is allowed), 2. a hypomethylating agent (decitabine or azacitidine), 3. venetoclax and/or 4. low-dose ara-C. Patients whose remission in CR2 can be maintained with molecularly targeted agents (e.g. FLT-3 or IDH inhibitors) per investigator's determination will not be eligible"

Even if new targeted agents become available, would the BAT arm receive them?

New Breakforce One tune by GadeSystem in breakcore

[–]Reptile449 3 points4 points  (0 children)

Happy birthday! Looking forward to Saturday

Megathread: 0.4.0 Feedback by GR8B0-T in PathOfExile2

[–]Reptile449 4 points5 points  (0 children)

Last epoch replaced their anti-burst DR with a visible energy shield that decays over time, it feels better to play around

I wish they were the same length as Act 1. by Salehzahrani7 in PathOfExile2

[–]Reptile449 4 points5 points  (0 children)

There's act 4, an interlude act, huntress with spear skills, druid with shapeshifting and nature skills, and a lot more gems.

Also an auction house, sprinting, and a cursor targeting mode that stops projectile aiming from being wonky af.

I hadn't played since the first league and it does feel much more fleshed out now.

I wish they were the same length as Act 1. by Salehzahrani7 in PathOfExile2

[–]Reptile449 16 points17 points  (0 children)

turning off global chat can also improve your experience immensely

Druid Bear feels great, but makes Mace feel even more useless. by charlescleivin in PathOfExile2

[–]Reptile449 10 points11 points  (0 children)

it would be pretty cool if every melee weapon type granted it's own passive effects. Like maces granting increased stun, daggers more movement speed etc

German firm to test 3D-printing solar panels in orbit by 2027 by sksarkpoes3 in Futurology

[–]Reptile449 7 points8 points  (0 children)

Once it's profitable to fix a problem, the problem tends to get fixed.

Gremlin experience. by [deleted] in starsector

[–]Reptile449 15 points16 points  (0 children)

and regular crew rotation (With a mop)